Cite

HARVARD Citation

    Martin, P. et al. (n.d.). Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas. Leukemia & lymphoma. 56 (11), pp. 3065-3070. [Online]. 
  
Back to record